QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 gt-biopharma-q2-eps-055-beats-068-estimate

GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.68) ...

 gt-biopharma-initiated-dosing-in-cohort-3-of-its-phase-1-dose-escalation-trial-of-gtb-3650-for-relapsed-or-refractory-cd33-expressing-hematologic-malignancies-plans-on-releasing-initial-phase-1-results-later-in-2025-following-completion-of-additional-dose-cohorts

The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful...

 gt-biopharma-q1-eps-033-beats-064-estimate

GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.64) ...

 gt-biopharma-appoints-michael-breen-as-ceo-for-two-year-term

-SEC Filing

 gt-biopharma-doses-initial-patient-in-phase-1-trial-of-gtb-3650-next-generation-trike-for-hematologic-cancer-treatment

"We are thrilled to initiate patient dosing with GTB-3650 in the Phase 1 trial to evaluate the potential in patients with h...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION